Ventana PD-L1 (SP142) Assay

被引：0

作者：

McGill, Rachel ^{[1
]}

Michail, Ramez ^{[1
]}

Miller, Brianne ^{[1
]}

Milton, Erica ^{[1
]}

Musyoka, Agnes ^{[1
]}

Musyoka, Rhoda ^{[1
]}

O'Conner, Jada ^{[1
]}

Ogunnaike, Morenike ^{[1
]}

Omeke, Soteria ^{[1
]}

Franklin, Gallop ^{[1
]}

Honeywell, Marlon S. ^{[1
]}

机构：

[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Inst Publ Hlth, Tallahassee, FL 32307 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：42 / 44

页数：3

共 12 条

[1] [Anonymous], 2021, TECENTRIQ (atezolizumab) [package insert]
[2] Breastcancer.org, SCREEN TEST
[3] Cancer Treatment Centers of America, 2022, TRIPL NEG BREAST CAN
[4] Drugs.com, 2022, WHAT IS COST TEC
[5] FDA, SSED
[6] FDA, 2019, VENTANA PD L1 SP142
[7] Genentech, 2021, Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer
[8] Gierach Gretchen L, 2010, Breast Dis, V32, P5, DOI 10.3233/BD-2010-0319
[9] Epidemiology of Triple-Negative Breast Cancer A Review
Howard, Frederick M.
Olopade, Olufunmilayo, I
[J]. CANCER JOURNAL, 2021, 27 (01) : 8 - 16
[10] McGarry WM, 2018, INT J WOMENS HLTH WE, V5, P087